Royce & Associates LP Trims Stock Position in Enovis Corporation $ENOV

Royce & Associates LP lessened its stake in Enovis Corporation (NYSE:ENOV) by 70.2% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 721,240 shares of the company’s stock after selling 1,697,683 shares during the period. Royce & Associates LP’s holdings in Enovis were worth $21,882,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Farther Finance Advisors LLC boosted its position in shares of Enovis by 42.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after purchasing an additional 367 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in shares of Enovis in the second quarter valued at approximately $46,000. SJS Investment Consulting Inc. grew its position in shares of Enovis by 30,340.0% during the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after acquiring an additional 1,517 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in shares of Enovis by 235.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,703 shares of the company’s stock worth $52,000 after acquiring an additional 1,195 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Trading Up 0.3%

NYSE ENOV opened at $25.49 on Monday. Enovis Corporation has a 12 month low of $21.00 and a 12 month high of $40.69. The company has a 50-day moving average of $24.27 and a 200-day moving average of $28.18. The company has a market cap of $1.46 billion, a P/E ratio of -1.23 and a beta of 1.46. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, February 26th. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The business had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. During the same quarter last year, the firm posted $0.98 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts predict that Enovis Corporation will post 2.79 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on ENOV. BTIG Research upped their price target on shares of Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday. Canaccord Genuity Group reduced their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. Evercore reiterated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. UBS Group restated a “buy” rating and issued a $50.00 price target on shares of Enovis in a research report on Monday, January 5th. Finally, Wells Fargo & Company increased their price objective on Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $47.43.

Insider Activity at Enovis

In related news, EVP Daniel A. Pryor sold 999 shares of the business’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total transaction of $27,172.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.70% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.